Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cesium-131 Brachytherapy in Recurrent Head and Neck Cancer
NCT02794675Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Dec 2016
- Primary completion
- Jul 2020
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cesium-131 in head and neck cancer (HNC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Disease Free Survival at 2 years. Started Dec 2016; status: completed.
02
Drugs
cesium-131
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02794675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794675.